PubMed:15897593
Annnotations
LitCoin-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-131 | Sentence | denotes | Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. |
| T2 | 132-140 | Sentence | denotes | PURPOSE: |
| T3 | 141-372 | Sentence | denotes | The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use. |
| T4 | 373-471 | Sentence | denotes | Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity. |
| T5 | 472-492 | Sentence | denotes | EXPERIMENTAL DESIGN: |
| T6 | 493-672 | Sentence | denotes | Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: |
| T7 | 673-851 | Sentence | denotes | Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays. |
| T8 | 852-1053 | Sentence | denotes | Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done. |
| T9 | 1054-1062 | Sentence | denotes | RESULTS: |
| T10 | 1063-1358 | Sentence | denotes | Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin. |
| T11 | 1359-1370 | Sentence | denotes | CONCLUSION: |
| T12 | 1371-1678 | Sentence | denotes | Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention. |
| T13 | 1679-1790 | Sentence | denotes | Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane. |
| T14 | 1791-1978 | Sentence | denotes | Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity. |
| T15 | 1979-2105 | Sentence | denotes | If successful, this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy. |
LitCoin-entities-OrganismTaxon-PD
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 391-394 | OrganismTaxon | denotes | 187 | NCBItxid:55511 |
| T2 | 688-693 | OrganismTaxon | denotes | human | NCBItxid:9606 |
| T3 | 878-882 | OrganismTaxon | denotes | mice | NCBItxid:10095|NCBItxid:10088 |
| T5 | 1169-1173 | OrganismTaxon | denotes | mice | NCBItxid:10095|NCBItxid:10088 |
LitCoin-entities
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| 1894 | 0-11 | ChemicalEntity | denotes | Dexrazoxane | MESH:D064730 |
| 1895 | 29-45 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | MESH:D001855 |
| 1896 | 84-93 | ChemicalEntity | denotes | etoposide | MESH:D005047 |
| 1897 | 98-110 | ChemicalEntity | denotes | daunorubicin | MESH:D003630 |
| 1898 | 119-130 | ChemicalEntity | denotes | doxorubicin | MESH:D004317 |
| 1899 | 145-159 | ChemicalEntity | denotes | anthracyclines | MESH:D018943 |
| 1900 | 160-172 | ChemicalEntity | denotes | daunorubicin | MESH:D003630 |
| 1901 | 177-188 | ChemicalEntity | denotes | doxorubicin | MESH:D004317 |
| 1902 | 197-215 | ChemicalEntity | denotes | epipodophyllotoxin | MESH:D011034 |
| 1903 | 216-225 | ChemicalEntity | denotes | etoposide | MESH:D005047 |
| 1904 | 318-334 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | MESH:D001855 |
| 1905 | 339-355 | DiseaseOrPhenotypicFeature | denotes | cardiac toxicity | MESH:D066126 |
| 1906 | 373-384 | ChemicalEntity | denotes | Dexrazoxane | MESH:D064730 |
| 1907 | 386-394 | ChemicalEntity | denotes | ICRF-187 | MESH:D064730 |
| 1908 | 434-447 | ChemicalEntity | denotes | anthracycline | MESH:D018943 |
| 1909 | 456-470 | DiseaseOrPhenotypicFeature | denotes | cardiotoxicity | MESH:D066126 |
| 1910 | 530-550 | DiseaseOrPhenotypicFeature | denotes | hematologic toxicity | MESH:D006402 |
| 1911 | 581-592 | ChemicalEntity | denotes | dexrazoxane | MESH:D064730 |
| 1912 | 688-693 | OrganismTaxon | denotes | human | NCBITaxon:9606 |
| 1913 | 698-704 | OrganismTaxon | denotes | murine | NCBITaxon:10090 |
| 1914 | 731-740 | ChemicalEntity | denotes | etoposide | MESH:D005047 |
| 1915 | 742-754 | ChemicalEntity | denotes | daunorubicin | MESH:D003630 |
| 1916 | 760-771 | ChemicalEntity | denotes | doxorubicin | MESH:D004317 |
| 1917 | 776-787 | ChemicalEntity | denotes | dexrazoxane | MESH:D064730 |
| 1918 | 878-882 | OrganismTaxon | denotes | mice | NCBITaxon:10090 |
| 1919 | 901-910 | ChemicalEntity | denotes | etoposide | MESH:D005047 |
| 1920 | 912-924 | ChemicalEntity | denotes | daunorubicin | MESH:D003630 |
| 1921 | 930-941 | ChemicalEntity | denotes | doxorubicin | MESH:D004317 |
| 1922 | 959-970 | ChemicalEntity | denotes | dexrazoxane | MESH:D064730 |
| 1923 | 1081-1092 | ChemicalEntity | denotes | dexrazoxane | MESH:D064730 |
| 1924 | 1101-1117 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | MESH:D001855 |
| 1925 | 1122-1133 | DiseaseOrPhenotypicFeature | denotes | weight loss | MESH:D015431 |
| 1926 | 1139-1151 | ChemicalEntity | denotes | daunorubicin | MESH:D003630 |
| 1927 | 1156-1165 | ChemicalEntity | denotes | etoposide | MESH:D005047 |
| 1928 | 1169-1173 | OrganismTaxon | denotes | mice | NCBITaxon:10090 |
| 1929 | 1252-1263 | ChemicalEntity | denotes | dexrazoxane | MESH:D064730 |
| 1930 | 1280-1296 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | MESH:D001855 |
| 1931 | 1298-1309 | DiseaseOrPhenotypicFeature | denotes | weight loss | MESH:D015431 |
| 1932 | 1328-1340 | DiseaseOrPhenotypicFeature | denotes | cytotoxicity | MESH:D064420 |
| 1933 | 1346-1357 | ChemicalEntity | denotes | doxorubicin | MESH:D004317 |
| 1934 | 1422-1433 | ChemicalEntity | denotes | dexrazoxane | MESH:D064730 |
| 1935 | 1499-1510 | ChemicalEntity | denotes | doxorubicin | MESH:D004317 |
| 1936 | 1548-1560 | ChemicalEntity | denotes | daunorubicin | MESH:D003630 |
| 1937 | 1718-1727 | ChemicalEntity | denotes | etoposide | MESH:D005047 |
| 1938 | 1778-1789 | ChemicalEntity | denotes | dexrazoxane | MESH:D064730 |
| 1939 | 1830-1840 | DiseaseOrPhenotypicFeature | denotes | metastases | MESH:D009362 |
| 1940 | 1851-1862 | ChemicalEntity | denotes | dexrazoxane | MESH:D064730 |
| 1941 | 1881-1890 | ChemicalEntity | denotes | etoposide | MESH:D005047 |
| 1942 | 1957-1977 | DiseaseOrPhenotypicFeature | denotes | hematologic toxicity | MESH:D006402 |
| 1943 | 2082-2091 | DiseaseOrPhenotypicFeature | denotes | cytotoxic | MESH:D064420 |
LitCoin-GeneOrGeneProduct-v0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 356-361 | GeneOrGeneProduct | denotes | limit |
| T2 | 386-390 | GeneOrGeneProduct | denotes | ICRF |
| T3 | 448-455 | GeneOrGeneProduct | denotes | induced |
| T4 | 722-727 | GeneOrGeneProduct | denotes | cells |
| T5 | 792-802 | GeneOrGeneProduct | denotes | determined |
| T6 | 878-882 | GeneOrGeneProduct | denotes | mice |
| T7 | 983-988 | GeneOrGeneProduct | denotes | range |
| T8 | 1016-1020 | GeneOrGeneProduct | denotes | full |
| T9 | 1093-1100 | GeneOrGeneProduct | denotes | reduced |
| T10 | 1169-1173 | GeneOrGeneProduct | denotes | mice |
| T11 | 1272-1279 | GeneOrGeneProduct | denotes | reduced |
| T12 | 1384-1392 | GeneOrGeneProduct | denotes | findings |
| T13 | 1434-1441 | GeneOrGeneProduct | denotes | reduces |
| T14 | 1462-1470 | GeneOrGeneProduct | denotes | activity |
| T15 | 1485-1493 | GeneOrGeneProduct | denotes | activity |
| T16 | 1561-1569 | GeneOrGeneProduct | denotes | activity |
| T17 | 1570-1576 | GeneOrGeneProduct | denotes | raises |
| T18 | 1651-1655 | GeneOrGeneProduct | denotes | call |
| T19 | 1824-1829 | GeneOrGeneProduct | denotes | brain |
| T20 | 1867-1871 | GeneOrGeneProduct | denotes | high |
| T21 | 2050-2060 | GeneOrGeneProduct | denotes | regulation |
| T22 | 2064-2068 | GeneOrGeneProduct | denotes | side |
LitCoin-GeneOrGeneProduct-v2
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 386-390 | GeneOrGeneProduct | denotes | ICRF |
| T2 | 1093-1100 | GeneOrGeneProduct | denotes | reduced |
| T3 | 1272-1279 | GeneOrGeneProduct | denotes | reduced |
| T4 | 1824-1829 | GeneOrGeneProduct | denotes | brain |
| T5 | 1867-1871 | GeneOrGeneProduct | denotes | high |
| T6 | 2064-2068 | GeneOrGeneProduct | denotes | side |
LitCoin-Disease-MeSH
| Id | Subject | Object | Predicate | Lexical cue | originalLabel |
|---|---|---|---|---|---|
| T1 | 339-355 | DiseaseOrPhenotypicFeature | denotes | cardiac toxicity | D066126 |
| T2 | 456-470 | DiseaseOrPhenotypicFeature | denotes | cardiotoxicity | D066126 |
| T3 | 542-550 | DiseaseOrPhenotypicFeature | denotes | toxicity | DISEASE |
| T4 | 1122-1133 | DiseaseOrPhenotypicFeature | denotes | weight loss | D015431 |
| T5 | 1298-1309 | DiseaseOrPhenotypicFeature | denotes | weight loss | D015431 |
| T6 | 1328-1340 | DiseaseOrPhenotypicFeature | denotes | cytotoxicity | DISEASE |
| T7 | 1824-1840 | DiseaseOrPhenotypicFeature | denotes | brain metastases | D001932 |
| T8 | 1969-1977 | DiseaseOrPhenotypicFeature | denotes | toxicity | DISEASE |
| T9 | 2082-2091 | DiseaseOrPhenotypicFeature | denotes | cytotoxic | DISEASE |
LitCoin-GeneOrGeneProduct-v3
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 386-390 | GeneOrGeneProduct | denotes | ICRF |
LitCoin_Mondo_095
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 673-684 | DiseaseOrPhenotypicFeature | denotes | Sensitivity | 0000605 |
LitCoin-MeSH-Disease-2
| Id | Subject | Object | Predicate | Lexical cue | ID: |
|---|---|---|---|---|---|
| T1 | 29-45 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE |
| T2 | 318-334 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE |
| T3 | 339-355 | DiseaseOrPhenotypicFeature | denotes | cardiac toxicity | D066126 |
| T4 | 456-470 | DiseaseOrPhenotypicFeature | denotes | cardiotoxicity | D066126 |
| T5 | 530-550 | DiseaseOrPhenotypicFeature | denotes | hematologic toxicity | DISEASE |
| T6 | 1101-1117 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE |
| T7 | 1122-1133 | DiseaseOrPhenotypicFeature | denotes | weight loss | D015431 |
| T8 | 1280-1296 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE |
| T9 | 1298-1309 | DiseaseOrPhenotypicFeature | denotes | weight loss | D015431 |
| T10 | 1328-1340 | DiseaseOrPhenotypicFeature | denotes | cytotoxicity | DISEASE |
| T11 | 1824-1840 | DiseaseOrPhenotypicFeature | denotes | brain metastases | D001932 |
| T12 | 1957-1977 | DiseaseOrPhenotypicFeature | denotes | hematologic toxicity | DISEASE |
| T13 | 2082-2091 | DiseaseOrPhenotypicFeature | denotes | cytotoxic | DISEASE |
LitCoin-MONDO_bioort2019
| Id | Subject | Object | Predicate | Lexical cue | #label |
|---|---|---|---|---|---|
| T1 | 29-45 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE |
| T2 | 318-334 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE |
| T3 | 339-355 | DiseaseOrPhenotypicFeature | denotes | cardiac toxicity | D066126 |
| T4 | 456-470 | DiseaseOrPhenotypicFeature | denotes | cardiotoxicity | D066126 |
| T5 | 530-550 | DiseaseOrPhenotypicFeature | denotes | hematologic toxicity | DISEASE |
| T6 | 1101-1117 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE |
| T7 | 1122-1133 | DiseaseOrPhenotypicFeature | denotes | weight loss | D015431 |
| T8 | 1280-1296 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE |
| T9 | 1298-1309 | DiseaseOrPhenotypicFeature | denotes | weight loss | D015431 |
| T10 | 1328-1340 | DiseaseOrPhenotypicFeature | denotes | cytotoxicity | DISEASE |
| T11 | 1824-1840 | DiseaseOrPhenotypicFeature | denotes | brain metastases | D001932 |
| T12 | 1957-1977 | DiseaseOrPhenotypicFeature | denotes | hematologic toxicity | DISEASE |
| T13 | 2082-2091 | DiseaseOrPhenotypicFeature | denotes | cytotoxic | DISEASE |
LitCoin-NCBITaxon-2
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 688-693 | OrganismTaxon | denotes | human |
| T2 | 698-704 | OrganismTaxon | denotes | murine |
| T3 | 878-882 | OrganismTaxon | denotes | mice |
| T4 | 1169-1173 | OrganismTaxon | denotes | mice |
| T5 | 1810-1818 | OrganismTaxon | denotes | patients |
LitCoin-Chemical-MeSH-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | ID: |
|---|---|---|---|---|---|
| T1 | 0-11 | ChemicalEntity | denotes | Dexrazoxane | D064730|http://purl.obolibrary.org/obo/CHEBI_50223 |
| T3 | 84-93 | ChemicalEntity | denotes | etoposide | D005047|http://purl.obolibrary.org/obo/CHEBI_4911 |
| T5 | 98-110 | ChemicalEntity | denotes | daunorubicin | D003630|http://purl.obolibrary.org/obo/CHEBI_64677|http://purl.obolibrary.org/obo/CHEBI_41977 |
| T8 | 119-130 | ChemicalEntity | denotes | doxorubicin | D004317|http://purl.obolibrary.org/obo/CHEBI_64816|http://purl.obolibrary.org/obo/CHEBI_28748 |
| T11 | 145-159 | ChemicalEntity | denotes | anthracyclines | D018943|http://purl.obolibrary.org/obo/CHEBI_49322|http://purl.obolibrary.org/obo/CHEBI_48120 |
| T14 | 160-172 | ChemicalEntity | denotes | daunorubicin | D003630|http://purl.obolibrary.org/obo/CHEBI_64677|http://purl.obolibrary.org/obo/CHEBI_41977 |
| T17 | 177-188 | ChemicalEntity | denotes | doxorubicin | D004317|http://purl.obolibrary.org/obo/CHEBI_64816|http://purl.obolibrary.org/obo/CHEBI_28748 |
| T20 | 197-215 | ChemicalEntity | denotes | epipodophyllotoxin | D011034|ChemicalEntity |
| T22 | 216-225 | ChemicalEntity | denotes | etoposide | D005047|http://purl.obolibrary.org/obo/CHEBI_4911 |
| T24 | 373-384 | ChemicalEntity | denotes | Dexrazoxane | D064730|http://purl.obolibrary.org/obo/CHEBI_50223 |
| T26 | 386-394 | ChemicalEntity | denotes | ICRF-187 | D064730|ChemicalEntity |
| T28 | 434-447 | ChemicalEntity | denotes | anthracycline | D018943|http://purl.obolibrary.org/obo/CHEBI_48120 |
| T30 | 581-592 | ChemicalEntity | denotes | dexrazoxane | D064730|http://purl.obolibrary.org/obo/CHEBI_50223 |
| T32 | 731-740 | ChemicalEntity | denotes | etoposide | D005047|http://purl.obolibrary.org/obo/CHEBI_4911 |
| T34 | 742-754 | ChemicalEntity | denotes | daunorubicin | D003630|http://purl.obolibrary.org/obo/CHEBI_64677|http://purl.obolibrary.org/obo/CHEBI_41977 |
| T37 | 760-771 | ChemicalEntity | denotes | doxorubicin | D004317|http://purl.obolibrary.org/obo/CHEBI_64816|http://purl.obolibrary.org/obo/CHEBI_28748 |
| T40 | 776-787 | ChemicalEntity | denotes | dexrazoxane | D064730|http://purl.obolibrary.org/obo/CHEBI_50223 |
| T42 | 901-910 | ChemicalEntity | denotes | etoposide | D005047|http://purl.obolibrary.org/obo/CHEBI_4911 |
| T44 | 912-924 | ChemicalEntity | denotes | daunorubicin | D003630|http://purl.obolibrary.org/obo/CHEBI_64677|http://purl.obolibrary.org/obo/CHEBI_41977 |
| T47 | 930-941 | ChemicalEntity | denotes | doxorubicin | D004317|http://purl.obolibrary.org/obo/CHEBI_64816|http://purl.obolibrary.org/obo/CHEBI_28748 |
| T50 | 959-970 | ChemicalEntity | denotes | dexrazoxane | D064730|http://purl.obolibrary.org/obo/CHEBI_50223 |
| T52 | 1081-1092 | ChemicalEntity | denotes | dexrazoxane | D064730|http://purl.obolibrary.org/obo/CHEBI_50223 |
| T54 | 1139-1151 | ChemicalEntity | denotes | daunorubicin | D003630|http://purl.obolibrary.org/obo/CHEBI_64677|http://purl.obolibrary.org/obo/CHEBI_41977 |
| T57 | 1156-1165 | ChemicalEntity | denotes | etoposide | D005047|http://purl.obolibrary.org/obo/CHEBI_4911 |
| T59 | 1252-1263 | ChemicalEntity | denotes | dexrazoxane | D064730|http://purl.obolibrary.org/obo/CHEBI_50223 |
| T61 | 1346-1357 | ChemicalEntity | denotes | doxorubicin | D004317|http://purl.obolibrary.org/obo/CHEBI_64816|http://purl.obolibrary.org/obo/CHEBI_28748 |
| T64 | 1422-1433 | ChemicalEntity | denotes | dexrazoxane | D064730|http://purl.obolibrary.org/obo/CHEBI_50223 |
| T66 | 1499-1510 | ChemicalEntity | denotes | doxorubicin | D004317|http://purl.obolibrary.org/obo/CHEBI_64816|http://purl.obolibrary.org/obo/CHEBI_28748 |
| T69 | 1548-1560 | ChemicalEntity | denotes | daunorubicin | D003630|http://purl.obolibrary.org/obo/CHEBI_64677|http://purl.obolibrary.org/obo/CHEBI_41977 |
| T72 | 1718-1727 | ChemicalEntity | denotes | etoposide | D005047|http://purl.obolibrary.org/obo/CHEBI_4911 |
| T74 | 1778-1789 | ChemicalEntity | denotes | dexrazoxane | D064730|http://purl.obolibrary.org/obo/CHEBI_50223 |
| T76 | 1851-1862 | ChemicalEntity | denotes | dexrazoxane | D064730|http://purl.obolibrary.org/obo/CHEBI_50223 |
| T78 | 1881-1890 | ChemicalEntity | denotes | etoposide | D005047|http://purl.obolibrary.org/obo/CHEBI_4911 |
LitCoin-training-merged
| Id | Subject | Object | Predicate | Lexical cue | #label | ID: |
|---|---|---|---|---|---|---|
| T78 | 1881-1890 | ChemicalEntity | denotes | etoposide | http://purl.obolibrary.org/obo/CHEBI_4911|D005047 | |
| T76 | 1851-1862 | ChemicalEntity | denotes | dexrazoxane | http://purl.obolibrary.org/obo/CHEBI_50223|D064730 | |
| T74 | 1778-1789 | ChemicalEntity | denotes | dexrazoxane | http://purl.obolibrary.org/obo/CHEBI_50223|D064730 | |
| T72 | 1718-1727 | ChemicalEntity | denotes | etoposide | http://purl.obolibrary.org/obo/CHEBI_4911|D005047 | |
| T69 | 1548-1560 | ChemicalEntity | denotes | daunorubicin | http://purl.obolibrary.org/obo/CHEBI_41977|http://purl.obolibrary.org/obo/CHEBI_64677|D003630 | |
| T66 | 1499-1510 | ChemicalEntity | denotes | doxorubicin | http://purl.obolibrary.org/obo/CHEBI_28748|http://purl.obolibrary.org/obo/CHEBI_64816|D004317 | |
| T64 | 1422-1433 | ChemicalEntity | denotes | dexrazoxane | http://purl.obolibrary.org/obo/CHEBI_50223|D064730 | |
| T61 | 1346-1357 | ChemicalEntity | denotes | doxorubicin | http://purl.obolibrary.org/obo/CHEBI_28748|http://purl.obolibrary.org/obo/CHEBI_64816|D004317 | |
| T59 | 1252-1263 | ChemicalEntity | denotes | dexrazoxane | http://purl.obolibrary.org/obo/CHEBI_50223|D064730 | |
| T57 | 1156-1165 | ChemicalEntity | denotes | etoposide | http://purl.obolibrary.org/obo/CHEBI_4911|D005047 | |
| T54 | 1139-1151 | ChemicalEntity | denotes | daunorubicin | http://purl.obolibrary.org/obo/CHEBI_41977|http://purl.obolibrary.org/obo/CHEBI_64677|D003630 | |
| T52 | 1081-1092 | ChemicalEntity | denotes | dexrazoxane | http://purl.obolibrary.org/obo/CHEBI_50223|D064730 | |
| T50 | 959-970 | ChemicalEntity | denotes | dexrazoxane | http://purl.obolibrary.org/obo/CHEBI_50223|D064730 | |
| T47 | 930-941 | ChemicalEntity | denotes | doxorubicin | http://purl.obolibrary.org/obo/CHEBI_28748|http://purl.obolibrary.org/obo/CHEBI_64816|D004317 | |
| T44 | 912-924 | ChemicalEntity | denotes | daunorubicin | http://purl.obolibrary.org/obo/CHEBI_41977|http://purl.obolibrary.org/obo/CHEBI_64677|D003630 | |
| T42 | 901-910 | ChemicalEntity | denotes | etoposide | http://purl.obolibrary.org/obo/CHEBI_4911|D005047 | |
| T40 | 776-787 | ChemicalEntity | denotes | dexrazoxane | http://purl.obolibrary.org/obo/CHEBI_50223|D064730 | |
| T37 | 760-771 | ChemicalEntity | denotes | doxorubicin | http://purl.obolibrary.org/obo/CHEBI_28748|http://purl.obolibrary.org/obo/CHEBI_64816|D004317 | |
| T34 | 742-754 | ChemicalEntity | denotes | daunorubicin | http://purl.obolibrary.org/obo/CHEBI_41977|http://purl.obolibrary.org/obo/CHEBI_64677|D003630 | |
| T32 | 731-740 | ChemicalEntity | denotes | etoposide | http://purl.obolibrary.org/obo/CHEBI_4911|D005047 | |
| T30 | 581-592 | ChemicalEntity | denotes | dexrazoxane | http://purl.obolibrary.org/obo/CHEBI_50223|D064730 | |
| T28 | 434-447 | ChemicalEntity | denotes | anthracycline | http://purl.obolibrary.org/obo/CHEBI_48120|D018943 | |
| T26 | 386-394 | ChemicalEntity | denotes | ICRF-187 | ChemicalEntity|D064730 | |
| T24 | 373-384 | ChemicalEntity | denotes | Dexrazoxane | http://purl.obolibrary.org/obo/CHEBI_50223|D064730 | |
| T22 | 216-225 | ChemicalEntity | denotes | etoposide | http://purl.obolibrary.org/obo/CHEBI_4911|D005047 | |
| T20 | 197-215 | ChemicalEntity | denotes | epipodophyllotoxin | ChemicalEntity|D011034 | |
| T17 | 177-188 | ChemicalEntity | denotes | doxorubicin | http://purl.obolibrary.org/obo/CHEBI_28748|http://purl.obolibrary.org/obo/CHEBI_64816|D004317 | |
| T14 | 160-172 | ChemicalEntity | denotes | daunorubicin | http://purl.obolibrary.org/obo/CHEBI_41977|http://purl.obolibrary.org/obo/CHEBI_64677|D003630 | |
| T11 | 145-159 | ChemicalEntity | denotes | anthracyclines | http://purl.obolibrary.org/obo/CHEBI_48120|http://purl.obolibrary.org/obo/CHEBI_49322|D018943 | |
| T8 | 119-130 | ChemicalEntity | denotes | doxorubicin | http://purl.obolibrary.org/obo/CHEBI_28748|http://purl.obolibrary.org/obo/CHEBI_64816|D004317 | |
| T5 | 98-110 | ChemicalEntity | denotes | daunorubicin | http://purl.obolibrary.org/obo/CHEBI_41977|http://purl.obolibrary.org/obo/CHEBI_64677|D003630 | |
| T3 | 84-93 | ChemicalEntity | denotes | etoposide | http://purl.obolibrary.org/obo/CHEBI_4911|D005047 | |
| T1 | 0-11 | ChemicalEntity | denotes | Dexrazoxane | http://purl.obolibrary.org/obo/CHEBI_50223|D064730 | |
| T99111 | 386-390 | GeneOrGeneProduct | denotes | ICRF | ||
| T13 | 2082-2091 | DiseaseOrPhenotypicFeature | denotes | cytotoxic | DISEASE | |
| T12 | 1957-1977 | DiseaseOrPhenotypicFeature | denotes | hematologic toxicity | DISEASE | |
| T55937 | 1824-1840 | DiseaseOrPhenotypicFeature | denotes | brain metastases | D001932 | |
| T10 | 1328-1340 | DiseaseOrPhenotypicFeature | denotes | cytotoxicity | DISEASE | |
| T9 | 1298-1309 | DiseaseOrPhenotypicFeature | denotes | weight loss | D015431 | |
| T13772 | 1280-1296 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE | |
| T7 | 1122-1133 | DiseaseOrPhenotypicFeature | denotes | weight loss | D015431 | |
| T6 | 1101-1117 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE | |
| T24848 | 530-550 | DiseaseOrPhenotypicFeature | denotes | hematologic toxicity | DISEASE | |
| T4 | 456-470 | DiseaseOrPhenotypicFeature | denotes | cardiotoxicity | D066126 | |
| T59842 | 339-355 | DiseaseOrPhenotypicFeature | denotes | cardiac toxicity | D066126 | |
| T2 | 318-334 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE | |
| T25709 | 29-45 | DiseaseOrPhenotypicFeature | denotes | myelosuppression | DISEASE | |
| T83458 | 1810-1818 | OrganismTaxon | denotes | patients | ||
| T50359 | 1169-1173 | OrganismTaxon | denotes | mice | ||
| T37556 | 878-882 | OrganismTaxon | denotes | mice | ||
| T77850 | 698-704 | OrganismTaxon | denotes | murine | ||
| T8704 | 688-693 | OrganismTaxon | denotes | human |